Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo

Molecular and Cellular Biology

Volumn 30, Issue 22, 2010, Pages 5394-5405

  De Clercq, Sarah ^a   Gembarska, Agnieszka ^a,b   Denecker, Geertrui ^a   Maetens, Marion ^a   Naessens, Michael ^a   Haigh, Katharina ^a   Haigh, Jody J ^a   Marine, Jean Christophe ^a,b  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; PROTEASOME; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; GENE OVEREXPRESSION; IN VIVO STUDY; LETHALITY; MOUSE; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION CARCINOGENESIS; TRANSGENE; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE; VASCULAR DISEASE;

ANIMALS; EMBRYO, MAMMALIAN; EPITOPES; FIBROBLASTS; KAPLAN-MEIER ESTIMATE; LYMPHOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TISSUE DISTRIBUTION; TRANSGENES; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

MUS; MUS MUSCULUS;

EID: 78649625045     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00330-10     Document Type: Article

References (57)

1. Adams, J. M., A. W. Harris, C. A. Pinkert, L. M. Corcoran, W. S. Alexander, S. Cory, R. D. Palmiter, and R. L. Brinster. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318:533-538.
2. Arjona, D., M. J. Bello, M. E. Alonso, A. Isla, J. M. De Campos, J. Vaquero, J. L. Sarasa, M. Gutierrez, and J. A. Rey. 2005. Real-time quantitative PCR analysis of regions involved in gene amplification reveals gene overdose in low-grade astrocytic gliomas. Diagn. Mol. Pathol. 14:224-229.
3. Barlow, C., S. Hirotsune, R. Paylor, M. Liyanage, M. Eckhaus, F. Collins, Y. Shiloh, J. N. Crawley, T. Ried, D. Tagle, and A. Wynshaw-Boris. 1996. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86:159-171.
4. Bueso-Ramos, C. E., Y. Yang, E. deLeon, P. McCown, S. A. Stass, and M. Albitar. 1993. The human MDM-2 oncogene is overexpressed in leukemias. Blood 82:2617-2623.
5. Danovi, D., E. Meulmeester, D. Pasini, D. Migliorini, M. Capra, R. Frenk, P. de Graaf, S. Francoz, P. Gasparini, A. Gobbi, K. Helin, P. G. Pelicci, A. G. Jochemsen, and J. C. Marine. 2004. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol. Cell. Biol. 24:5835-5843.
6. de Graaf, P., N. A. Little, Y. F. Ramos, E. Meulmeester, S. J. Letteboer, and A. G. Jochemsen. 2003. Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. J. Biol. Chem. 278:38315-38324.
7. Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery, Jr., J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221.
8. Eischen, C. M., J. D. Weber, M. F. Roussel, C. J. Sherr, and J. L. Cleveland. 1999. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13:2658-2669.
9. Finch, R. A., D. B. Donoviel, D. Potter, M. Shi, A. Fan, D. D. Freed, C. Y. Wang, B. P. Zambrowicz, R. Ramirez-Solis, A. T. Sands, and N. Zhang. 2002. mdmx is a negative regulator of p53 activity in vivo. Cancer Res. 62:3221-3225.
10. Francoz, S., P. Froment, S. Bogaerts, S. De Clercq, M. Maetens, G. Doumont, E. Bellefroid, and J. C. Marine. 2006. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc. Natl. Acad. Sci. U. S. A. 103:3232-3237.
11. Ganguli, G., J. Abecassis, and B. Wasylyk. 2000. MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis. EMBO J. 19:5135-5147.
12. Ganguli, G., and B. Wasylyk. 2003. p53-independent functions of MDM2. Mol. Cancer Res. 1:1027-1035.
13. Gorrini, C., M. Squatrito, C. Luise, N. Syed, D. Perna, L. Wark, F. Martinato, D. Sardella, A. Verrecchia, S. Bennett, S. Confalonieri, M. Cesaroni, F. Marchesi, M. Gasco, E. Scanziani, M. Capra, S. Mai, P. Nuciforo, T. Crook, J. Lough, and B. Amati. 2007. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 448:1063-1067.
14. Grier, J. D., W. Yan, and G. Lozano. 2002. Conditional allele of mdm2 which encodes a p53 inhibitor. Genesis 32:145-147.
15. Gu, J., H. Kawai, L. Nie, H. Kitao, D. Wiederschain, A. G. Jochemsen, J. Parant, G. Lozano, and Z. M. Yuan. 2002. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J. Biol. Chem. 277:19251-19254.
16. Han, X., G. Garcia-Manero, T. J. McDonnell, G. Lozano, L. J. Medeiros, L. Xiao, G. Rosner, M. Nguyen, M. Fernandez, Y. A. Valentin-Vega, J. Barboza, D. M. Jones, G. Z. Rassidakis, H. M. Kantarjian, and C. E. Bueso-Ramos. 2007. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod. Pathol. 20:54-62.
17. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
18. Hayashi, S., P. Lewis, L. Pevny, and A. P. McMahon. 2002. Efficient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain. Mech. Dev. 119(Suppl. 1):S97-S101.
19. Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25-27.
20. Jacks, T., L. Remington, B. O. Williams, E. M. Schmitt, S. Halachmi, R. T. Bronson, and R. A. Weinberg. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4:1-7.
21. Jones, S. N., A. R. Hancock, H. Vogel, L. A. Donehower, and A. Bradley. 1998. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 95:15608-15612.
22. Jones, S. N., A. E. Roe, L. A. Donehower, and A. Bradley. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206-208.
23. Kawai, H., D. Wiederschain, H. Kitao, J. Stuart, K. K. Tsai, and Z. M. Yuan. 2003. DNA damage-induced MDMX degradation is mediated by MDM2. J. Biol. Chem. 278:45946-45953.
24. Kubbutat, M. H., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387:299-303.
25. Laurie, N. A., S. L. Donovan, C. S. Shih, J. Zhang, N. Mills, C. Fuller, A. Teunisse, S. Lam, Y. Ramos, A. Mohan, D. Johnson, M. Wilson, C. Rodriguez-Galindo, M. Quarto, S. Francoz, S. M. Mendrysa, R. K. Guy, J. C. Marine, A. G. Jochemsen, and M. A. Dyer. 2006. Inactivation of the p53 pathway in retinoblastoma. Nature 444:61-66.
26. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
27. Marine, J. C., M. A. Dyer, and A. G. Jochemsen. 2007. MDMX: from bench to bedside. J. Cell Sci. 120:371-378.
28. Marine, J. C., S. Francoz, M. Maetens, G. Wahl, F. Toledo, and G. Lozano. 2006. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ. 13:927-934.
29. Marine, J. C., and G. Lozano. 2010. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ. 17:93-102.
30. Matsumura, T., Y. Yoshihama, T. Kimura, S. Shintani, and R. E. Alcalde. 1996. p53 and MDM2 expression in oral squamous cell carcinoma. Oncology 53:308-312.
31. Migliorini, D., D. Danovi, E. Colombo, R. Carbone, P. G. Pelicci, and J. C. Marine. 2002. Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation. J. Biol. Chem. 277:7318-7323.
32. Migliorini, D., E. Lazzerini Denchi, D. Danovi, A. Jochemsen, M. Capillo, A. Gobbi, K. Helin, P. G. Pelicci, and J. C. Marine. 2002. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol. Cell. Biol. 22:5527-5538.
33. Moller, M. B., O. Nielsen, and N. T. Pedersen. 1999. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities. Mod. Pathol. 12:1010-1016.
34. Momand, J., D. Jung, S. Wilczynski, and J. Niland. 1998. The MDM2 gene amplification database. Nucleic Acids Res. 26:3453-3459.
35. Montes de Oca Luna, R., D. S. Wagner, and G. Lozano. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203-206.
36. Nyabi, O., M. Naessens, K. Haigh, A. Gembarska, S. Goossens, M. Maetens, S. De Clercq, B. Drogat, L. Haenebalcke, S. Bartunkova, I. De Vos, B. De Craene, M. Karimi, G. Berx, A. Nagy, P. Hilson, J. C. Marine, and J. J. Haigh. 2009. Efficient mouse transgenesis using Gateway-compatible ROSA26 locus targeting vectors and F1 hybrid ES cells. Nucleic Acids Res. 37:e55.
37. Oliner, J. D., K. W. Kinzler, P. S. Meltzer, D. L. George, and B. Vogelstein. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83.
38. Pan, Y., and J. Chen. 2003. MDM2 promotes ubiquitination and degradation of MDMX. Mol. Cell. Biol. 23:5113-5121.
39. Parant, J., A. Chavez-Reyes, N. A. Little, W. Yan, V. Reinke, A. G. Jochemsen, and G. Lozano. 2001. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet. 29:92-95.
40. Park, S., J. S. Kim, L. Tessarollo, J. D. Owens, L. Peng, S. S. Han, S. Tae Chung, T. A. Torrey, W. C. Cheung, R. D. Polakiewicz, N. McNeil, T. Ried, J. F. Mushinski, H. C. Morse III, and S. Janz. 2005. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasm in mice. Cancer Res. 65:1306-1315.
41. Reifenberger, G., L. Liu, K. Ichimura, E. E. Schmidt, and V. P. Collins. 1993. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53:2736-2739.
42. Schmitt, C. A., M. E. McCurrach, E. de Stanchina, R. R. Wallace-Brodeur, and S. W. Lowe. 1999. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13:2670-2677.
43. Sharp, D. A., S. A. Kratowicz, M. J. Sank, and D. L. George. 1999. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J. Biol. Chem. 274:38189-38196.
44. Sherr, C. J., and R. A. DePinho. 2000. Cellular senescence: mitotic clock or culture shock? Cell 102:407-410.
45. Shieh, S. Y., M. Ikeda, Y. Taya, and C. Prives. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334.
46. Stad, R., N. A. Little, D. P. Xirodimas, R. Frenk, A. J. van der Eb, D. P. Lane, M. K. Saville, and A. G. Jochemsen. 2001. Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep. 2:1029-1034.
47. Steinman, H. A., K. M. Hoover, M. L. Keeler, A. T. Sands, and S. N. Jones. 2005. Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development. Oncogene 24:7935-7940.
48. Tanimura, S., S. Ohtsuka, K. Mitsui, K. Shirouzu, A. Yoshimura, and M. Ohtsubo. 1999. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett. 447:5-9.
49. Toledo, F., and G. M. Wahl. 2006. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6:909-923.
50. Tronche, F., C. Kellendonk, O. Kretz, P. Gass, K. Anlag, P. C. Orban, R. Bock, R. Klein, and G. Schutz. 1999. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat. Genet. 23:99-103.
51. Vafa, O., M. Wade, S. Kern, M. Beeche, T. K. Pandita, G. M. Hampton, and G. M. Wahl. 2002. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol. Cell 9:1031-1044.
52. Valentin-Vega, Y. A., J. A. Barboza, G. P. Chau, A. K. El-Naggar, and G. Lozano. 2007. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum. Pathol. 38:1553-1562.
53. Vassilev, L. T., B. T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, and E. A. Liu. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848.
54. Wade, M., Y. V. Wang, and G. M. Wahl. 2010. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 20:299-309.
55. Wang, Y. V., M. Leblanc, M. Wade, A. G. Jochemsen, and G. M. Wahl. 2009. Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell 16:33-43.
56. Watanabe, T., T. Hotta, A. Ichikawa, T. Kinoshita, H. Nagai, T. Uchida, T. Murate, and H. Saito. 1994. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 84:3158-3165.
57. Xiong, S., C. S. Van Pelt, A. C. Elizondo-Fraire, G. Liu, and G. Lozano. 2006. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc. Natl. Acad. Sci. U. S. A. 103:3226-3231.